Interactive Features

Test Your Knowledge

Quiz: Tolerability of Ruxolitinib Plus Azacitidine for Advanced Phase MPN

01/12/2021

True or False: Ruxolitinib plus azacitidine was not well-tolerated among patients with advanced phase MPN/post-MPN AML in the 1250 Phazar clinical trial.

True or False: Ruxolitinib plus...

01/12/2021

Oncology

Test Your Knowledge

Quiz: Promise of Guadecitabine Maintenance Therapy for High Risk MDS/AML

01/04/2021

True or false: Guadecitabine maintenance therapy after allogeneic stem cell transplantation has yielded promising survival rates and manageable safety in high-risk patients with MDS/AML.

True or false: Guadecitabine...

01/04/2021

Oncology

Test Your Knowledge

Quiz: Has Rigosertib Plus Azacitidine Shown Tolerability in Patients With MDS?

11/09/2020

True or False: A combo regimen comprising rigosertib and azacitidine was shown to be well tolerated in patients with MDS, chronic myelomonocytic leukemia, and AML.

True or False: A combo regimen...

11/09/2020

Oncology

Test Your Knowledge

Quiz: Adding Pevonedistat to Azacitidine in Higher-Risk MDS

09/25/2020

True or False: Adding pevonedistat plus azacitidine improves OS, EFS, and response rates in patients with higher-risk MDS.

True or False: Adding...

09/25/2020

Oncology

Test Your Knowledge

Quiz: Is the Oral Combo Decitabine–Cedazuridine Beneficial for Adults With MDS?

09/17/2020

True or False: The FDA approved an oral combination of decitabine and cedazuridine for the treatment of adults with myelodysplastic syndromes.

True or False: The FDA approved...

09/17/2020

Oncology

Test Your Knowledge

Quiz: Should Patients With PV Given Hydroxyurea be Actively Monitored?

07/07/2020

True or False: Patients with PV given hydroxyurea to maintain blood count control should be actively monitored, with extra attention paid to signs and symptoms of hydroxyurea intolerance.

True or False: Patients with PV...

07/07/2020

Oncology

Test Your Knowledge

Quiz: Ropeginterferon Alfa-2b Versus Hydroxyurea for PV

05/05/2020

True or False: Ropeginterferon alfa-2b demonstrates improved responses over time in comparison to hydroxyurea for polycythemia vera.

True or False: Ropeginterferon...

05/05/2020

Oncology

Test Your Knowledge

Quiz: Is Ruxolitinib Safe Long-Term for Treating Polycythemia Vera?

04/13/2020

True or false: Long-term ruxolitinib is a safe and effective therapy option for patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea.

True or false: Long-term...

04/13/2020

Oncology

Test Your Knowledge

Quiz: Enasidenib as Treatment for Patients with IDH2-Mutated MDS

03/30/2020

True or false: Enasidenib was shown to be poorly tolerated in a study of patients with relapsed or refractory IDH2-mutated MDS.

True or false: Enasidenib was...

03/30/2020

Oncology

Test Your Knowledge

Quiz: Conditioning Before Transplantation for Patients With MDS

03/12/2020

True or False: Standard myeloablative conditioning before allogeneic hematopoietic stem-cell transplantation is superior to conditioning with fludarabine and treosulfan in patients with MDS.

True or False: Standard...

03/12/2020

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology